Clinical and regulatory intelligence for Idiopathic Pulmonary Fibrosis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 3

Relevant assets

Nintedanib →

Phase →

Pirfenidone →

Relevant companies

Aurobindo Pharma →

Recent signals(3)

StrategyJuly 5, 2026

Aurobindo Pharma's Pirfenidone ANDA Submission Receives AP Status

Aurobindo Pharma has submitted ANDA212597 for Pirfenidone, which has received Abbreviated Approval (AP) status.

ClinicalJuly 3, 2026

Phase IIb Trial of Autoantibody Reduction Therapy for Progressive IPF Initiated

A Phase IIb trial is underway to evaluate a multi-component autoantibody reduction therapy for progressive IPF.

ClinicalJuly 2, 2026

Phase 2 Trial of Nintedanib DPI in Idiopathic Pulmonary Fibrosis Initiated by Mannkind Corporation

Mannkind Corporation is conducting Phase 2 trial of inhaled Nintedanib DPI in patients with IPF, focusing on safety and preliminary efficacy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Idiopathic Pulmonary Fibrosis →

Pulmonology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.